Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589773089> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2589773089 abstract "Abstract Background: 95% of HIV- and HCV-infections among PWHs occurred with use of contaminated blood products prior to 1985. Overall, 20% to 90% of PWHs in developed countries have HIV- and/or HCV-infection. We compared country-specific public health approaches, judicial activities, and compensation for these viral infections. Methods: Reports from hemophilia organizations, national ministries of health, published articles, and the World Federation of Hemophilia were reviewed. Results: Except for the United States, the number of PWHs who developed HCV-infection from contaminated blood products was 1.5 to 3-fold as great as for HIV-infection- as a result of delayed use of heat-treated blood products, importation in late 1984 of HCV-infected non-heat treated blood products from the United States, and failure to use surrogate laboratory marker hepatitis screening tests. Compensation funds for HIV-infected PWHs were established in Japan ($521,000 at Dx); France ($305,000 at Dx; $102,000 for AIDS); the United States ($115,000 at Dx); Ireland ($106,000 at Dx); the United Kingdom ($55,000 at Dx); Australia ($48,000 at Dx); Canada ($13,000 at Dx/$18,000/yr); Germany ($12,000/yr for HIV; $24,000/yr for AIDS); and Italy ($6,000/yr; $82,000 at death). Compensation has also been provided to HCV-infected PWHs in Ireland ($266,000 at Dx); Canada ($251,000 at Dx); the United Kingdom ($33,000 at Dx; $42,000 if w/liver damage); and Italy ($10,000/yr; $37,000 at death). Conclusions: In most developed countries, despite a greater number of HCV-versus HIV-infected PWHs, markedly less attention has been paid to HCV-infected PWHs. All countries should review HCV-related blood safety decisions made in the 1980s and consider providing compensation to HCV-infected PWHs. A comparison of national responses to HIV and HCV infections from blood products Country -PWH (thousands) % PWH with HIV:HCV Man-dated HIV ELISA (date) Man-dated heat Rx factor (date) Anti-HBc marker screening (date) Nat’l Funds for HIV/HCV among PWHs (year) Nat’l Panels for HIV/HCV decisions (year) USA-20 50%:30% Mar 85 Oct 84 Oct 84 96/none 95/none Italy- 8.7 23%:55% Mar 85 Jul 85 None 92/98 92/05 GDR- 6 47%:90% Oct 85 Oct 85 None 95/none 94/none UK-6 28%:80% Oct 85 Jun 85 None 88/03 87/05 France-4 50%:90% Aug 85 Oct 85 None 89/none 91/none Japan-3.4 60%:90% Nov 86 Jun 86 None 88/none 96/none Canada-2 40%:88% Nov 85 Jul 85 None 89/98 97/none Australia-1.5 31%:90% May 85 Jan 85 None 89/none 88/none Ireland-0.3 36%:76% Oct 85 Feb 85 None 91/97 91/97" @default.
- W2589773089 created "2017-03-03" @default.
- W2589773089 creator A5037456539 @default.
- W2589773089 creator A5042702852 @default.
- W2589773089 creator A5051032646 @default.
- W2589773089 creator A5061766064 @default.
- W2589773089 creator A5064266275 @default.
- W2589773089 creator A5067434226 @default.
- W2589773089 date "2005-11-16" @default.
- W2589773089 modified "2023-09-27" @default.
- W2589773089 title "National Responses to HIV Versus HCV-Infection from Virally Contaminated Blood Products among Persons with Hemophilia (PWH): More Different Than Alike." @default.
- W2589773089 doi "https://doi.org/10.1182/blood.v106.11.3213.3213" @default.
- W2589773089 hasPublicationYear "2005" @default.
- W2589773089 type Work @default.
- W2589773089 sameAs 2589773089 @default.
- W2589773089 citedByCount "0" @default.
- W2589773089 crossrefType "journal-article" @default.
- W2589773089 hasAuthorship W2589773089A5037456539 @default.
- W2589773089 hasAuthorship W2589773089A5042702852 @default.
- W2589773089 hasAuthorship W2589773089A5051032646 @default.
- W2589773089 hasAuthorship W2589773089A5061766064 @default.
- W2589773089 hasAuthorship W2589773089A5064266275 @default.
- W2589773089 hasAuthorship W2589773089A5067434226 @default.
- W2589773089 hasConcept C138816342 @default.
- W2589773089 hasConcept C142724271 @default.
- W2589773089 hasConcept C159047783 @default.
- W2589773089 hasConcept C203014093 @default.
- W2589773089 hasConcept C2522874641 @default.
- W2589773089 hasConcept C2776029263 @default.
- W2589773089 hasConcept C2776408679 @default.
- W2589773089 hasConcept C2776455275 @default.
- W2589773089 hasConcept C2780014101 @default.
- W2589773089 hasConcept C3013748606 @default.
- W2589773089 hasConcept C71924100 @default.
- W2589773089 hasConcept C99454951 @default.
- W2589773089 hasConceptScore W2589773089C138816342 @default.
- W2589773089 hasConceptScore W2589773089C142724271 @default.
- W2589773089 hasConceptScore W2589773089C159047783 @default.
- W2589773089 hasConceptScore W2589773089C203014093 @default.
- W2589773089 hasConceptScore W2589773089C2522874641 @default.
- W2589773089 hasConceptScore W2589773089C2776029263 @default.
- W2589773089 hasConceptScore W2589773089C2776408679 @default.
- W2589773089 hasConceptScore W2589773089C2776455275 @default.
- W2589773089 hasConceptScore W2589773089C2780014101 @default.
- W2589773089 hasConceptScore W2589773089C3013748606 @default.
- W2589773089 hasConceptScore W2589773089C71924100 @default.
- W2589773089 hasConceptScore W2589773089C99454951 @default.
- W2589773089 hasLocation W25897730891 @default.
- W2589773089 hasOpenAccess W2589773089 @default.
- W2589773089 hasPrimaryLocation W25897730891 @default.
- W2589773089 hasRelatedWork W1621024649 @default.
- W2589773089 hasRelatedWork W2000967870 @default.
- W2589773089 hasRelatedWork W2014571665 @default.
- W2589773089 hasRelatedWork W2024707990 @default.
- W2589773089 hasRelatedWork W2038449539 @default.
- W2589773089 hasRelatedWork W2123135658 @default.
- W2589773089 hasRelatedWork W2339946342 @default.
- W2589773089 hasRelatedWork W2419238389 @default.
- W2589773089 hasRelatedWork W2435552101 @default.
- W2589773089 hasRelatedWork W7457640 @default.
- W2589773089 isParatext "false" @default.
- W2589773089 isRetracted "false" @default.
- W2589773089 magId "2589773089" @default.
- W2589773089 workType "article" @default.